12/1
12:48 pm
mygn
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today [Yahoo! Finance]
Low
Report
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today [Yahoo! Finance]
11/28
02:42 am
mygn
How Recent Developments Are Shaping the Myriad Genetics Investment Story [Yahoo! Finance]
Low
Report
How Recent Developments Are Shaping the Myriad Genetics Investment Story [Yahoo! Finance]
11/25
04:56 pm
mygn
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health [Yahoo! Finance]
Low
Report
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health [Yahoo! Finance]
11/25
04:15 pm
mygn
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
Low
Report
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
11/25
01:54 pm
mygn
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
01:00 pm
mygn
Why Myriad Genetics (MYGN) Stock Is Up Today [Yahoo! Finance]
Medium
Report
Why Myriad Genetics (MYGN) Stock Is Up Today [Yahoo! Finance]
11/18
01:18 pm
mygn
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/14
08:36 am
mygn
1 High-Flying Stock with Solid Fundamentals and 2 We Question [Yahoo! Finance]
Medium
Report
1 High-Flying Stock with Solid Fundamentals and 2 We Question [Yahoo! Finance]
11/12
01:27 pm
mygn
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/11
04:10 pm
mygn
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know [Yahoo! Finance]
Low
Report
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know [Yahoo! Finance]
11/11
12:21 pm
mygn
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Piper Sandler from $9.00 to $8.50. They now have an "overweight" rating on the stock.
Low
Report
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Piper Sandler from $9.00 to $8.50. They now have an "overweight" rating on the stock.
11/11
09:00 am
mygn
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Medium
Report
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
11/10
08:46 am
mygn
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs [Yahoo! Finance]
Low
Report
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs [Yahoo! Finance]
11/10
08:30 am
mygn
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
Low
Report
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
11/10
03:48 am
mygn
The Top 5 Analyst Questions From Myriad Genetics's Q3 Earnings Call [Yahoo! Finance]
Medium
Report
The Top 5 Analyst Questions From Myriad Genetics's Q3 Earnings Call [Yahoo! Finance]
11/10
01:41 am
mygn
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025 [Yahoo! Finance]
Medium
Report
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025 [Yahoo! Finance]
11/9
07:03 pm
mygn
Does Neogen's (NEOG) CFO Transition Signal a New Phase for Its Financial Strategy? [Yahoo! Finance]
Medium
Report
Does Neogen's (NEOG) CFO Transition Signal a New Phase for Its Financial Strategy? [Yahoo! Finance]
11/7
01:14 am
mygn
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
08:30 am
mygn
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
Medium
Report
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
11/5
10:49 am
mygn
Myriad Genetics (NASDAQ:MYGN) had its price target raised by analysts at Wells Fargo & Company from $6.00 to $6.50. They now have an "equal weight" rating on the stock.
Medium
Report
Myriad Genetics (NASDAQ:MYGN) had its price target raised by analysts at Wells Fargo & Company from $6.00 to $6.50. They now have an "equal weight" rating on the stock.
11/4
02:03 pm
mygn
Myriad Genetics (NASDAQ:MYGN) had its price target raised by analysts at TD Cowen from $8.00 to $9.00. They now have a "hold" rating on the stock.
Low
Report
Myriad Genetics (NASDAQ:MYGN) had its price target raised by analysts at TD Cowen from $8.00 to $9.00. They now have a "hold" rating on the stock.
11/4
12:12 pm
mygn
Why Myriad Genetics (MYGN) Stock Is Down Today [Yahoo! Finance]
Low
Report
Why Myriad Genetics (MYGN) Stock Is Down Today [Yahoo! Finance]
11/4
11:04 am
mygn
Myriad Genetics (NASDAQ:MYGN) had its "hold" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Myriad Genetics (NASDAQ:MYGN) had its "hold" rating reaffirmed by analysts at Cowen Inc.
11/4
08:05 am
mygn
Myriad Genetics (NASDAQ:MYGN) was given a new $8.00 price target on by analysts at UBS Group AG.
High
Report
Myriad Genetics (NASDAQ:MYGN) was given a new $8.00 price target on by analysts at UBS Group AG.
11/3
04:05 pm
mygn
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
High
Report
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution